Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16855
Country/Region: Nigeria
Year: 2014
Main Partner: Centre for Integrated Health Programs
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $32,843,400 Additional Pipeline Funding: N/A

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

BRIDGES_PLUS is a locally driven effort to ensure the continued improvement, expansion, and long-term sustainability of comprehensive, family-centred, quality-focused HIV prevention, care, and treatment services in four high HIV prevalent states (Benue, Kaduna, Kogi and Gombe) in Nigeria .

The BRIDGES_PLUS provide community and hospital based care and treatment services using an integrated approach, effective linkages (e.g. “hub and spoke” model) and service coordination to ensure continuity of comprehensive service delivery; local capacity building for stewardship to sustain services on the long term. Service delivery activities will be supported through over 600 service delivery entities, including public and private health facilities and CBO. The project will make an important contribution to PEPFAR’s global targets and take significant strides towards sustainability. CIHP will implement quality HIV care, support and treatment services across all thematic areas in line with national guidelines, protocols, and regimens. CIHP is building on it's experience implementing ART and other care services for individuals infected and affected by HIV and AIDS to rapidly scale coverage and access to of ART and PMTCT services to greater than 50% of individuals requiring such services and the promotion of a combination of prevention approach, prioritizing youth, Most-at-Risk Population and with balanced gender-sensitive messaging to address the identified barriers to prevention and access to care and treatment.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $4,241,911
Care: Orphans and Vulnerable Children (HKID) $2,543,735
Care: TB/HIV (HVTB) $1,187,125
Care: Pediatric Care and Support (PDCS) $298,300
Laboratory Infrastructure (HLAB) $4,387,569
Strategic Information (HVSI) $951,113
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Blood Safety (HMBL) $21,077
Biomedical Prevention: Injection Safety (HMIN) $61,711
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,388,377
Sexual Prevention: Other Sexual Prevention (HVOP) $607,348
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $3,977,554
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $12,293,247
Treatment: Pediatric Treatment (PDTX) $884,333
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
BS_COLL By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory 2015 15,300
BS_COLL By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory that are identified as reactive for HIV 2015 340
BS_COLL Number of whole blood collections each year by the NBTS ne2rk 2015 17,000
GEND_GBV Age: 0-9 2015 39
GEND_GBV Age: 10-14 2015 79
GEND_GBV Age: 15-17 2015 117
GEND_GBV Age: 18-24 2015 69
GEND_GBV Age: 25+ 2015 34
GEND_GBV By PEP service provision (related to sexual violence services provided) 2015 262
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2015 76
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2015 262
GEND_GBV Number of people receiving post-GBV care 2015 338
GEND_GBV Sex: Female 2015 225
GEND_GBV Sex: Male 2015 113
GEND_GBV Sum of Age disaggregates 2015 338
GEND_GBV Sum of Sex disaggregates 2015 338
HTS_TST Age/sex: <1 Female 2015 6,552
HTS_TST Age/sex: <1 Female 2015 6,552
HTS_TST Age/sex: <1 Male 2015 6,296
HTS_TST Age/sex: <1 Male 2015 6,296
HTS_TST Age/sex: 1-4 Female 2015 2,691
HTS_TST Age/sex: 1-4 Female 2015 2,691
HTS_TST Age/sex: 1-4 Male 2015 2,568
HTS_TST Age/sex: 1-4 Male 2015 2,568
HTS_TST Age/sex: 10-14 Female 2015 2,385
HTS_TST Age/sex: 10-14 Female 2015 2,385
HTS_TST Age/sex: 10-14 Male 2015 2,324
HTS_TST Age/sex: 10-14 Male 2015 2,324
HTS_TST Age/sex: 15-19 Female 2015 48,692
HTS_TST Age/sex: 15-19 Female 2015 48,692
HTS_TST Age/sex: 15-19 Male 2015 25,774
HTS_TST Age/sex: 15-19 Male 2015 25,774
HTS_TST Age/sex: 20-24 Female 2015 131,989
HTS_TST Age/sex: 20-24 Female 2015 131,989
HTS_TST Age/sex: 20-24 Male 2015 53,352
HTS_TST Age/sex: 20-24 Male 2015 53,352
HTS_TST Age/sex: 25-49 Female 2015 294,556
HTS_TST Age/sex: 25-49 Female 2015 294,556
HTS_TST Age/sex: 25-49 Male 2015 167,608
HTS_TST Age/sex: 25-49 Male 2015 167,608
HTS_TST Age/sex: 5-9 Female 2015 1,070
HTS_TST Age/sex: 5-9 Female 2015 1,070
HTS_TST Age/sex: 5-9 Male 2015 1,040
HTS_TST Age/sex: 5-9 Male 2015 1,040
HTS_TST Age/sex: 50+ Female 2015 5,351
HTS_TST Age/sex: 50+ Female 2015 5,351
HTS_TST Age/sex: 50+ Male 2015 5,198
HTS_TST Age/sex: 50+ Male 2015 5,198
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 12,698
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 12,227
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 480,589
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 251,932
HTS_TST Aggregated Age/sex: <15 Female 2015 12,698
HTS_TST Aggregated Age/sex: <15 Male 2015 12,227
HTS_TST Aggregated Age/sex: 15+ Female 2015 480,589
HTS_TST Aggregated Age/sex: 15+ Male 2015 251,932
HTS_TST By Test Result: Negative 2015 733,191
HTS_TST By Test Result: Negative 2015 733,191
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 757,446
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 757,446
HTS_TST Sum of Age/Sex disaggregates 2015 757,446
HTS_TST Sum of Age/Sex disaggregates 2015 757,446
HTS_TST Sum of Aggregated Age/Sex <15 2015 24,925
HTS_TST Sum of Aggregated Age/Sex <15 2015 24,925
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 732,521
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 732,521
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 757,446
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 757,446
HTS_TST Sum of Test Result disaggregates 2015 757,446
HTS_TST Sum of Test Result disaggregates 2015 757,446
HTS_TST_POS By Test Result: Positive 2015 24,255
HTS_TST_POS By Test Result: Positive 2015 24,255
LAB_ACC By site support type: Direct Service Delivery (DSD) 2015 2
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 2
LAB_ACC Sum of Support Type disaggregates 2015 2
LAB_CAP By clinical laboratories 2015 111
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 111
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 111
LAB_CAP Sum of Site Support Type disaggregates 2015 111
OVC_ACC Age: <1 2015 1,579
OVC_ACC Age: 1-4 2015 6,579
OVC_ACC Age: 10-14 2015 6,316
OVC_ACC Age: 15-17 2015 3,684
OVC_ACC Age: 18+ 2015 789
OVC_ACC Age: 5-9 2015 7,368
OVC_ACC Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2015 26,315
OVC_ACC Sex: Female 2015 13,421
OVC_ACC Sex: Male 2015 12,894
OVC_ACC Sum of Age disaggregates 2015 26,315
OVC_ACC Sum of Sex disaggregates 2015 26,315
OVC_SERV Age: <1 2015 5,263
OVC_SERV Age: 1-4 2015 21,929
OVC_SERV Age: 10-14 2015 21,052
OVC_SERV Age: 15-17 2015 12,280
OVC_SERV Age: 18+ 2015 2,631
OVC_SERV Age: 5-9 2015 24,560
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2015 87,715
OVC_SERV Sex: Female 2015 44,735
OVC_SERV Sex: Male 2015 42,980
OVC_SERV Sum of Age disaggregates 2015 87,715
OVC_SERV Sum of Sex disaggregates 2015 87,715
PMTCT_ARV Life-long ART (including Option B+) 2015 6,296
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 1,028
PMTCT_ARV Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 5,396
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 14,119
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 12,848
PMTCT_ARV Single-dose nevirapine (with or without tail) 2015 128
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 3,481
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 2,815
PMTCT_ARV Sum of New and Current disaggregates 2015 6,296
PMTCT_ARV Sum of Regimen Type disaggregates 2015 12,848
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 6,296
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 1,028
PMTCT_ARV_NGI Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 5,396
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 14,119
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 12,848
PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 2015 128
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 3,481
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 2,815
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 6,296
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 12,848
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 4,240
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 8,608
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 642
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 14,119
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 12,848
PMTCT_EID Sum of Infant Age disaggregates 2015 12,848
PMTCT_STAT By: Known positives at entry 2015 5,647
PMTCT_STAT By: Number of new positives identified 2015 8,471
PMTCT_STAT Number of new ANC and L&D clients 2015 246,289
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 224,123
PMTCT_STAT Sum of Positives Status disaggregates 2015 14,118
PMTCT_STAT_NGI By: Known positives at entry 2015 5,647
PMTCT_STAT_NGI By: Number of new positives identified 2015 8,471
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 246,289
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 224,123
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 14,118
PP_PREV Age/sex: 10-14 Female 2015 2,115
PP_PREV Age/sex: 10-14 Male 2015 2,033
PP_PREV Age/sex: 15-19 Female 2015 2,538
PP_PREV Age/sex: 15-19 Male 2015 2,439
PP_PREV Age/sex: 20-24 Female 2015 6,347
PP_PREV Age/sex: 20-24 Male 2015 6,097
PP_PREV Age/sex: 25-49 Female 2015 9,519
PP_PREV Age/sex: 25-49 Male 2015 9,146
PP_PREV Age/sex: 50+ Female 2015 635
PP_PREV Age/sex: 50+ Male 2015 610
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 41,479
PP_PREV Sum of Age/Sex disaggregates 2015 41,479
PP_PREV Total number of people in the target population 2015 150,697
TB_ART Age: 0-4 2015 25
TB_ART Age: 15+ 2015 2,307
TB_ART Age: 5-14 2015 123
TB_ART Aggregated Age: <15 2015 147
TB_ART Aggregated Age: 15+ 2015 2,308
TB_ART Female 2015 1,252
TB_ART Known HIV-positive 2015 1,056
TB_ART Male 2015 1,203
TB_ART Newly tested 2015 1,399
TB_ART Sum of Aggregated Age disaggregates 2015 2,455
TB_ART Sum of Sex disaggregates 2015 2,455
TB_ART Sum of Test Status disaggregates 2015 2,455
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2015 2,455
TX_CURR Age/Sex: <1 Female 2015 184
TX_CURR Age/Sex: <1 Male 2015 207
TX_CURR Age/Sex: 1-4 Female 2015 867
TX_CURR Age/Sex: 1-4 Male 2015 977
TX_CURR Age/Sex: 15+ Female 2015 66,494
TX_CURR Age/Sex: 15+ Male 2015 32,751
TX_CURR Age/Sex: 5-14 Female 2015 1,576
TX_CURR Age/Sex: 5-14 Male 2015 1,777
TX_CURR Aggregated Age/Sex: <1 Female 2015 184
TX_CURR Aggregated Age/Sex: <1 Male 2015 207
TX_CURR Aggregated Age/Sex: <15 Female 2015 2,626
TX_CURR Aggregated Age/Sex: <15 Male 2015 2,961
TX_CURR Aggregated Age/Sex: 15+ Female 2015 66,495
TX_CURR Aggregated Age/Sex: 15+ Male 2015 32,751
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 104,833
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 5
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 66
TX_CURR Sum of age/sex disaggregates 2015 5,588
TX_CURR Sum of Aggregated Age/Sex <15 2015 5,587
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 99,246
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 104,833
TX_CURR_NGI Age/Sex: <1 Female 2015 184
TX_CURR_NGI Age/Sex: <1 Male 2015 207
TX_CURR_NGI Age/Sex: 1-4 Female 2015 867
TX_CURR_NGI Age/Sex: 1-4 Male 2015 977
TX_CURR_NGI Age/Sex: 15+ Female 2015 66,494
TX_CURR_NGI Age/Sex: 15+ Male 2015 32,751
TX_CURR_NGI Age/Sex: 5-14 Female 2015 1,576
TX_CURR_NGI Age/Sex: 5-14 Male 2015 1,777
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 184
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 207
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 2,626
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 2,961
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 66,495
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 32,751
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 104,833
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 104,833
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 5,587
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 99,246
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 104,833
TX_NEW Aggregated Grouping by Age: <1 Male 2015 168
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 160
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 1,064
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 1,200
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 27,744
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 12,464
TX_NEW By Age/Sex: <1 Female 2015 160
TX_NEW By Age/Sex: <1 Male 2015 168
TX_NEW By Age/Sex: 1-4 Female 2015 213
TX_NEW By Age/Sex: 1-4 Male 2015 240
TX_NEW By Age/Sex: 10-14 Female 2015 426
TX_NEW By Age/Sex: 10-14 Male 2015 492
TX_NEW By Age/Sex: 15-19 Female 2015 4,162
TX_NEW By Age/Sex: 15-19 Male 2015 1,870
TX_NEW By Age/Sex: 20-24 Female 2015 6,936
TX_NEW By Age/Sex: 20-24 Male 2015 3,116
TX_NEW By Age/Sex: 25-49 Female 2015 11,095
TX_NEW By Age/Sex: 25-49 Male 2015 4,986
TX_NEW By Age/Sex: 5-9 Female 2015 266
TX_NEW By Age/Sex: 5-9 Male 2015 300
TX_NEW By Age/Sex: 50+ Female 2015 5,549
TX_NEW By Age/Sex: 50+ Male 2015 2,493
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 42,472
TX_NEW Pregnancy status 2015 2,219
TX_NEW Sum of Age/Sex disaggregates 2015 42,472
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 42,472
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 571
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 26,831
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,142
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,713
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 26,831
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 28,544
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,342
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 33,581
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 672
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 31,566
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,343
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 2,015
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 31,566
Cross Cutting Budget Categories and Known Amounts Total: $1,784,116
Renovation $998,625
Gender: Gender Equality $254,373
Promoting gender-related policies and laws that increase legal protection
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Implementation
Motor Vehicles: Purchased $325,476
Condoms: Policy, Tools, and Services $205,642
Key Issues Identified in Mechanism
enumerations.Malaria (PMI)
Tuberculosis
Family Planning